Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Heartburn Medications Do Not Ease Asthma Symptoms

By R&D Editors | April 10, 2009

The predominance of heartburn among asthma sufferers led many specialists to suspect that acid reflux could be a trigger for the coughing, wheezing, and breathlessness of asthma. In fact, it has become standard practice to prescribe heartburn medication to people with poorly controlled asthma, even if they don’t have overt acid reflux symptoms.

But a new study of adults with inadequate asthma control without significant heartburn shows that heartburn medication does not help control their asthma symptoms. The study, conducted by the American Lung Association’s Asthma Clinical Research Centers at 20 US sites, demonstrated that participants who took esomeprazole (Nexium) had as many asthma episodes as participants who were given an inactive pill, or placebo.

‘This study goes against the idea that mild or silent acid reflux contributes to uncontrolled asthma,’ says Mario Castro, MD, a Washington University pulmonary specialist at Barnes-Jewish Hospital who led the study in St. Louis. ‘It establishes that heartburn medications are not indicated for adults with uncontrolled asthma when they have mild or no symptoms of acid reflux.’

However, Castro says prescription heartburn medication is still indicated for those with severe heartburn and poorly controlled asthma because it might improve asthma control in some of these patients.

The practice of prescribing heartburn medication to patients with poorly controlled asthma was a product of common sense — not only did asthma patients often suffer from heartburn, doctors had evidence that stomach acid traveling up the esophagus could get into the lungs and cause coughing. In addition, studies in laboratory animals showed that if the lower esophagus is exposed to acid, it could send nerve signals that loop back to the lungs and cause airway constriction.

But, past investigations into the potential benefit of heartburn medication for asthma control were inconclusive, showing either no effect or a small benefit.

The current study enrolled 412 patients who had poorly controlled asthma despite being treated with inhaled corticosteroids. But they had either no or very mild acid reflux symptoms. Each participant was randomly assigned to receive either 80 milligrams of esomeprazole or a placebo daily. Then for 24 weeks, they kept a daily record of their asthma symptoms. Every four weeks their lung function was tested, and they completed asthma questionnaires.

In both the placebo and treatment groups, episodes of poor asthma control occurred with similar frequency. Occurrences of an urgent care visit for an asthma attack; a reduction in lung function; a course of corticosteroids, which reduce inflammation; or increased use of bronchodilators, which relax the airway muscles, did not differ significantly between the treatment and placebo groups. Night awakening due to asthma occurred on one or more occasions in about half of the participants, and the rate did not differ significantly between the two groups.

‘Despite using four-times the typical dose of the heartburn medication, we achieved no improvement in asthma symptoms, control or exacerbation rates,’ says Castro, also professor of medicine and pediatrics in the Division of Pulmonary and Critical Care Medicine.

Although the participants were mostly free of heartburn symptoms, when the researchers measured acid reflux using probes placed in the esophagus for 24 hours, they found that about 40 percent of the study participants had some acid reflux. But even the participants with measureable acid reflux did not achieve greater control of their asthma when they received esomeprazole.

The multicenter network is currently conducting a parallel study in children ages six to 17 who have poorly controlled asthma and no heartburn. Called SARCA (Studying Acid Reflux in Children with Asthma), the investigation will try to determine whether heartburn medication can help control asthma in younger patients.

‘Acid reflux is fairly common in children,’ Castro says. ‘And we know that a finding in adults doesn’t necessarily apply to children, so we feel it’s important to evaluate whether acid suppression in children with uncontrolled asthma is effective.’

Release Date: April 8, 2009
Source: Washington University in St. Louis

Related Articles Read More >

New dangers in the woods — and the hope that research offers us
Novel mass spectrometry solution simplifies insight gathering into macromolecular complexes
ENPICOM launches display solution to accelerate antibody selection while maximizing precision
Thermo Fisher Scientific autoimmune-testing instruments now available in the U.S.
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2022 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars